RedHill Biopharma Ltd. (RDHL)
2.93
-0.06 (-2.01%)
At close: Mar 24, 2025, 3:40 PM
2.90
-1.14%
After-hours: Mar 24, 2025, 07:56 PM EDT
-2.01% (1D)
| Bid | 2.8 |
| Market Cap | 9.34K |
| Revenue (ttm) | 3.26K |
| Net Income (ttm) | 11.98K |
| EPS (ttm) | -302.63 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | 211 |
| Analyst | n/a |
| Ask | 2.99 |
| Volume | 29,744 |
| Avg. Volume (20D) | 93,237 |
| Open | 2.92 |
| Previous Close | 2.99 |
| Day's Range | 2.86 - 3.06 |
| 52-Week Range | 2.47 - 20.27 |
| Beta | 3.83 |
About RDHL
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development pr...
Sector Healthcare
IPO Date Jan 7, 2013
Employees 53
Stock Exchange NASDAQ
Ticker Symbol RDHL
Website https://www.redhillbio.com
7 months ago
+25.06%
Redhill Biopharma shares are trading higher after ...
Unlock content with
Pro Subscription
7 months ago
+10.76%
Redhill Biopharma shares are trading higher after the company announced results from multiple in vivo studies.
